We demonstrate that afatinib, a second-generation EGFR-TKI, exhibits stronger anticancer effects compared to gefitinib in oral cancer cell lines lacking the EGFR790M mutation. The gene discussed is EGFR; the disease is lip and oral cavity carcinoma.